Bioventus INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Bioventus Inc. reported a significant return to net income and increased Adjusted EBITDA in 2025, driven by strategic divestitures and new product launches, despite a slight dip in overall net sales.
NASDAQ
Bioventus Inc. details its financial performance for the year ended December 31, 2024, highlighting net sales, net loss, and strategic business developments in its annual report.
NASDAQ
Bioventus Inc. released its 2023 annual report, highlighting financial performance and strategic developments across its pain treatment, surgical solutions, and restorative therapies segments.